These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35644725)

  • 41. Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.
    de Meza MM; Blokx WAM; Bonenkamp HJ; Blank CU; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JWB; Haanen JB; Hospers GAP; Kapiteijn EW; van Not OJ; Piersma D; van Rijn RS; Stevense-Den Boer MA; van der Veldt AAM; Vreugdenhil G; van den Eertwegh AJM; Suijkerbuijk KPM; Wouters MWJM
    Int J Cancer; 2023 Jul; 153(2):389-398. PubMed ID: 36843260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study.
    Nanda JK; Dusza SW; Navarrete-Dechent C; Liopyris K; Marghoob AA; Marchetti MA
    JAMA Dermatol; 2021 Jan; 157(1):79-83. PubMed ID: 32936222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
    Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
    Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
    Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination.
    van Willigen WW; Bloemendal M; Boers-Sonderen MJ; de Groot JWB; Koornstra RHT; van der Veldt AAM; Haanen JBAG; Boudewijns S; Schreibelt G; Gerritsen WR; de Vries IJM; Bol KF
    Oncoimmunology; 2020 Mar; 9(1):1738814. PubMed ID: 33457087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.
    Dimitriou F; Hauschild A; Mehnert JM; Long GV
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-22. PubMed ID: 35658500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
    Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
    Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.
    Nakamura Y; Namikawa K; Kiniwa Y; Kato H; Yamasaki O; Yoshikawa S; Maekawa T; Matsushita S; Takenouchi T; Inozume T; Nakai Y; Fukushima S; Saito S; Otsuka A; Fujimoto N; Isei T; Baba N; Matsuya T; Tanaka R; Kaneko T; Onishi M; Kuwatsuka Y; Nagase K; Onuma T; Nomura M; Umeda Y; Yamazaki N
    Eur J Cancer; 2022 Nov; 176():78-87. PubMed ID: 36194906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
    Carreau NA; Pavlick AC
    Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
    Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
    Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
    Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
    Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM
    Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience.
    Archibald WJ; Victor AI; Strawderman MS; Maggiore RJ
    J Geriatr Oncol; 2020 Apr; 11(3):496-502. PubMed ID: 31303463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
    Wong SK; Blum SM; Sun X; Da Silva IP; Zubiri L; Ye F; Bai K; Zhang K; Ugurel S; Zimmer L; Livingstone E; Schadendorf D; Serra-Bellver P; Muñoz-Couselo E; Ortiz C; Lostes J; Huertas RM; Arance A; Pickering L; Long GV; Carlino MS; Buchbinder EI; Vázquez-Cortés L; Jara-Casas D; Márquez-Rodas I; González-Espinoza IR; Balko JM; Menzies AM; Sullivan RJ; Johnson DB
    Eur J Cancer; 2023 Mar; 181():188-197. PubMed ID: 36680880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.